Kornimate/medical-research-clean huggingface dataset:
perioperative lidocaine and ketamine in abdominal surgery

Conditions: Postoperative Pain

Summary: the investigators propose to test the hypothesis that perioperative infusions of lidocaine and/or ketamine reduce opioid consumption and pain scores in adults recovering from elective inpatient abdominal surgery.

the investigators propose a prospective, randomized, double-blind, placebo-controlled clinical trial (rct) with a factorial design. adults 18 to 80 years old having elective inpatient open or laparoscopic abdominal surgery with general anesthesia lasting 2 hours or longer will be included in this study.

Eligibility criteria:
inclusion criteria: * adults 18 to 80 years old * elective inpatient open or laparoscopic abdominal surgery * general anesthesia lasting 2 hours or longer. exclusion criteria: * 1. planned postoperative mechanical ventilation * 2. planned regional anesthesia/analgesia * 3. perioperative gabapentin, magnesium, or nitrous oxide use * 4. pregnancy or breastfeeding * 5. morbid obesity (bmi ≥ 35 kg/m2) * 6. american society of anesthesiologists (asa) physical status iv-v * 7. allergy to study medications * 8. contraindication to lidocaine (severe cardiac arrhythmia) * 9. contraindication to ketamine (psychiatric disorder, substance abuse, uncontrolled hypertension, pulmonary hypertension, increased intracranial or intraocular pressure, use of monoamine oxidase inhibitors) * 10. chronic preoperative opioid use (≥ 90 morphine mg equivalents per day for \> 3 months) * 11. significant preoperative hepatic dysfunction (alanine aminotransferase or aspartate aminotransferase levels \> 5 times normal) or planned liver transplantation * 12. preoperative cardiac failure (left ventricular ejection fraction ≤ 40%) * 13. unable to communicate or comprehend study instructions

Keywords: multimodal analgesia lidocaine ketamine abdominal surgery
development of a family-based transition planning program for culturally-diverse youth on the autism spectrum

Conditions: Autism Spectrum Disorder; Family Relations

Summary: the goal of this clinical study is to develop a community-based program to support family members of transition-aged youth on the autism spectrum to help them plan for the future. the main aims of the study are: 1. to develop the families forward program 2. to conduct proof-of-concept testing of the families forward program participants will complete surveys before and after participating in the program and will participate in exit interviews at the end of the program.

the families forward (focusing on relationships, well-being, and responsibility ahead) program aims to increase family members' active planning for the transition to adulthood in the context of autism. the program is designed to enable flexible delivery for families of youth who are diverse across autism features, co-occurring conditions, service needs, cultural values and preferences, and readiness to engage in planning. the program will be delivered collaboratively with community organizations that support individuals on the autism spectrum and/or their families. the current project aims to conduct proof-of-concept testing with a culturally-diverse sample of families of transition-aged youth on the autism spectrum. parents / primary caregivers will participate in 6-7 individual, personalized sessions that incorporate aspects of skill-building (communication, goal-setting, problem-solving, systems navigation), education about services, and motivational interviewing. youth will be invited to participate in 3 of the sessions along with their parent / primary caregiver. participants will complete surveys before and after participating in the program and will participate in exit interviews at the end of the program. the investigators will assess indicators of acceptability, feasibility, and improvement on proposed mediators and outcomes.

Eligibility criteria:
inclusion criteria: * family inclusion criteria 1. parents or primary caregivers of transition-aged youth on the autism spectrum: 1. have one or more child(ren) on the autism spectrum who is/are ages 14-21 years old 2. identify as the parent, legal guardian, and/or primary caregiver of the youth 3. speak english fluently 4. reside in massachusetts 2. youth on the autism spectrum: 1. have an autism diagnosis or identify as autistic 2. age 14-21 3. have ability to communicate verbally or in written format in english 4. reside in massachusetts exclusion criteria: none
photo-medicine-guided dual approach for reoperation of sentinel lymph nodes in locally recurrent breast cancer patients

Conditions: Breast Cancer; Locally Recurrent Breast Cancer; Sentinel Lymph Node Biopsy (SLNB); Reoperation; ICG (indocyanine Green)

Summary: sentinel lymph node biopsy (slnb) is essential for staging and treatment planning in early breast cancer patients. as a less invasive procedure, it has replaced axillary lymph node dissection (alnd) by reducing complications and improving patient outcomes. however, the 10-year local recurrence rate for breast cancer is approximately 2-10%, and the role of slnb in the surgical management of recurrent breast cancer remains unclear. according to the nccn guidelines and korean breast cancer treatment recommendations, surgical management for recurrent breast cancer includes mastectomy and axillary lymph node surgery for patients who have previously undergone breast-conserving surgery and radiotherapy. for axillary recurrence, surgery is recommended if feasible, followed by radiotherapy. conversely, the asco guidelines recommend slnb for surgically resectable recurrent breast cancer, and recent studies have reported promising outcomes for repeat sentinel lymph node biopsy (reslnb). vugts g et al. demonstrated an 80.1% tumor-negative rate with reslnb, suggesting that alnd could be avoided in many cases. although reslnb offers the advantage of reducing unnecessary invasive procedures and associated complications, challenges remain due to disrupted lymphatic pathways in patients who have previously undergone surgery and radiotherapy. additionally, research on the long-term prognosis of these patients is still limited. this study aims to evaluate the detection rate of sentinel lymph nodes using a photo-medicine-based dual localization technique that combines traditional radiotracer methods with indocyanine green-fluorescence (icg-f) in patients undergoing reslnb for locally recurrent breast cancer.


Eligibility criteria:
inclusion criteria: * patients with ipsilateral locally recurrent breast cancer who previously underwent ipsilateral axillary surgery. * female patients aged 18 years or older. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * patients who voluntarily decide to participate in the study and provide written informed consent. exclusion criteria: * patients with distant metastases. * patients who previously underwent ipsilateral mastectomy. * pregnant or breastfeeding women. * patients with a general condition that impairs the ability to understand or provide informed consent.

Keywords: breast cancer locally recurrent breast cancer sentinel lymph node biopsy (slnb) reoperation icg(indocyanine green)
effect of chronobıologıcal nutrıtıon on premature babıes

Conditions: Nutrition, Healthy

Summary: the aim of this study is to determine the effect of chronobiological nutrition approach on the growth and breastfeeding processes of premature babies. it will be carried out in a randomized controlled experimental design. in the study, it is planned to have 2 groups as experimental and control. as a result of the power analysis using the g power 3.0.10 program, 90% power; a total of at least 78 samples were found to be sufficient in the study with a 5% margin of error (n1: 39; n2: 39). however, considering that the case could be lost, it was decided to increase it by 20% to 94 babies. infants will be assigned to groups using a stratified sequential block randomization method. premature babies will be stratified by week of gestation, birth weight and sex, and then an equal number of babies will be assigned to each group by blocking. the appointment of premature infants will be decided by sequential block randomization. after the descriptive information of the babies assigned to the groups is recorded in the questionnaire, the experimental group will be fed by applying the chronobiological nutrition approach. the control group will be fed without applying the chronobiological nutrition approach. the discharge times will be calculated for both groups.


Eligibility criteria:
inclusion criteria: * being treated in the nicu * gestation week is between 30 and 36 * the delivery took place in the hospital where the study was conducted. * 70% of the daily enteral feeding is done with breast milk exclusion criteria: * the baby is less than 30 weeks of gestation and greater than 36 weeks of gestation. * having neurological sequelae * having grade 4 intraventricular bleeding * the development of problems such as sepsis, nec, which may change the general condition * being followed in invasive mechanical ventilation * receiving narcotic analgesics and sedation * the baby has been shipped from outside * having undergone gastrointestinal (gis) surgery or having gis anomaly

Keywords: premature chorobiological nutrition breastfeeding processes
effects of deep brain stimulation (dbs) frequency on neural synchrony

Conditions: Parkinson's Disease

Summary: the purpose of this study is to evaluate the effects of low frequency deep brain stimulation on subthalamic nucleus neural synchrony. low frequency stimulation does not improve the cardinal motor signs of parkinson's disease, and may be beneficial only for gait and speech. this study will provide insight into what the effects of low frequency stimulation are on neural synchrony.


Eligibility criteria:
inclusion criteria: * a diagnosis of idiopathic parkinson's disease, with bilateral symptoms at hoehn and yahr stage greater than or equal to ii. * documented improvement in motor signs on versus off dopaminergic medication, with a change in the unified parkinson's disease rating scale motor (updrs iii) score of \>= 30% off to on medication. * the presence of complications of medication such as wearing off signs, fluctuating responses and/or dyskinesias, and/or medication refractory tremor, and/or impairment in the quality of life on or off medication due to these factors. * subjects should be on stable doses of medications, which should remain unchanged until the dbs system is activated. after the dbs system is optimized (during which time the overall medication dose may be reduced to avoid discomfort and complications such as dyskinesias) the medication dose should remain unchanged, if possible, for the duration of the study. * treatment with carbidopa/levodopa, and with a dopamine agonist at the maximal tolerated doses as determined by a movement disorders neurologist. * age \> 18 exclusion criteria: * subjects with significant cognitive impairment and/or dementia as determined by a standardized neuropsychological battery. * subjects with clinically active depression, defined according to the diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) criteria and as scored on a validated depression assessment scale. * subjects with very advanced parkinson's disease, hoehn and yahr stage 5 on medication (non-ambulatory). * age \> 80. * subjects with an implanted electronic device such as a neurostimulator, cardiac pacemaker/defibrillator or medication pump. * subjects, who are pregnant, are capable of becoming pregnant, or who are breast feeding. * patients with cortical atrophy out of proportion to age or focal brain lesions that could indicate a non-idiopathic movement disorder as determined by mri * subjects having a major comorbidity increasing the risk of surgery (prior stroke, severe hypertension, severe diabetes, or need for chronic anticoagulation other than aspirin). * subjects having any prior intracranial surgery. * subjects with a history of seizures. * subjects, who are immunocompromised. * subjects with an active infection. * subjects, who require diathermy, electroconvulsive therapy (ect), or transcranial magnetic stimulation (tms) to treat a chronic condition. * subjects, who have an inability to comply with study follow-up visits. * subjects, who are unable to understand or sign the informed consent

Keywords: parkinson's disease dbs deep brain stimulation subthalamic nucleus
effects of dha on pro-resolving anti-inflammatory mediators in obese patients undergoing weight-loss treatment

Conditions: Obesity; Inflammation

Summary: comparative, randomized, placebo-controlled, single-centre, single-blind clinical trial to assess the effectiveness of providing additional dha omega-3 fatty acids supplements to increase the levels of pro-resolving and anti-inflammatory lipid mediators and decrease the biological markers of chronic inflammation in obese patients following a weight-loss programme.

will include obese patients (bmi between 30 and 35) who are following a standardized, multidisciplinary weight-loss programme (pronokal® method), which consists of a very-low-calorie diet based on protein packets and vegetables with a low glycemic index, into which natural foods are gradually reintroduced, accompanied by physical exercise and emotional support. patients who are being treated with acetylsalicylic acid (asa), non-steroidal anti-inflammatory drugs (nsaids), corticoids or thiazolidinedione antidiabetic drugs (glitazones); and patients with immune disorders (rheumatoid arthritis, lupus, etc.) and/or inflammatory disease (ulcerative colitis, crohn's disease, etc.) who may alter the biological markers of inflammation,will be excluded. treatment: in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme, the patients will receive an additional 500 mg/day supplement of dha omega-3 fatty acids in capsule form (study group) or a placebo capsule (control group). the follow up will be 6 months and patients will be monitored over the course of 6 control visits: baseline, 7 days, 15 days, 30 days, 60 days and 180 days. the main objective is to assess the effectiveness of providing additional dha supplements to increase the levels of pro-resolving and anti-inflammatory lipid mediators and decrease the biological markers of chronic inflammation in obese patients following a weight-loss programme.

Eligibility criteria:
inclusion criteria: * age between 18 and 75 years * obese patients with body mass index between 30 and 35 * patients who, regardless of their inclusion in this study, are going to follow the standardized weight-loss programme (pronokal® method) * patients who agree to participate and sign the informed consent form exclusion criteria: * treatment with omega-3 fatty acid supplements for other reasons during the month prior to inclusion in the trial * treatment with acetylsalicylic acid (asa), non-steroidal anti-inflammatory drugs (nsaids), corticoids or thiazolidinedione antidiabetic drugs (glitazones) * pregnant or nursing patients * haemopathy, including clotting disorders * treatment with dicoumarin anticoagulants (sintrom®) * cancer or a history of cancer who have not received the oncologist's release * type 1 or type 2 diabetes mellitus * immune disorders (rheumatoid arthritis, lupus, etc.) and/or inflammatory disease (ulcerative colitis, crohn's disease, etc.) that may alter the biological markers of inflammation * patients not expected to attend monitoring visits

Keywords: docosahexaenoic acids fatty acids, omega-3 obesity inflammation
ai-based skeleton recognition system for rehabilitation exercise in breast cancer survivors: a randomized controlled trial

Conditions: Musculoskeletal Symptoms; Breast Cancer; Endocrine Therapy; Aromatase Inhibitors

Summary: this study aims to develop and evaluate an artificial intelligence (ai)-based skeletal recognition system designed to support real-time, interactive rehabilitation exercise (re programs. the goal is to mitigate musculoskeletal symptoms associated with endocrine therapy in breast cancer survivors.endocrine therapy remains a cornerstone in the treatment of hormone receptor-positive breast cancer, typically extending over 5 to 10 years. while the therapeutic benefits of endocrine therapy are well established, agents such as aromatase inhibitors frequently induce musculoskeletal symptoms (ms), including joint pain, stiffness (particularly morning stiffness), carpal tunnel syndrome, tenosynovitis, myalgia, and muscle weakness. these symptoms, which may be continuous or intermittent, can affect both central (spine, hips, shoulders) and peripheral joints (elbows, wrists, knees, feet), severely compromising patients' quality of life (qol). although physical exercise has been demonstrated to alleviate these symptoms, adherence to adequate exercise regimens remains suboptimal among patients. furthermore, there is no consensus on the optimal type, duration, or intensity of exercise interventions, and standardized protocols are lacking. recognizing exercise as a long-term behavior, we are developing a home-based, ai-assisted rehabilitation program tailored to the specific needs of patients undergoing endocrine therapy.


Eligibility criteria:
inclusion criteria: * 1. pathologically confirmed hormone receptor-positive breast cancer (stage i, ii, iii). 2. initiation of treatment with aromatase inhibitors (e.g., anastrozole, letrozole, exemestane). 3. postmenopausal women, including those with surgically induced menopause. 4. clear consciousness, no cognitive or communication impairments, and able to comply with the intervention. 5. informed consent obtained, with voluntary participation in the study. 6. bone and joint symptoms with a brief pain inventory (bpi) score of ≥3, or presence of at least one of the following risk factors: elevated bone turnover markers, reduced vitamin d levels, increased inflammatory cytokines, elevated c-reactive protein, or elevated rheumatoid factor. 7. not participating in any physical therapy or exercise-based interventions that may interfere with this study. exclusion criteria: - 1. recurrence of breast cancer or distant metastasis. 2. presence of other malignancies. 3. diagnosed rheumatoid arthritis, bone and joint trauma, or other severe bone and joint diseases. 4. bone mineral density t-score \<-2.5. 5. presence of absolute contraindications to exercise.
a study to investigate the safety, tolerability and efficacy of hlx60 combination with hlx10 in subjects with advanced or metastatic solid tumors

Conditions: Advanced or Metastatic Solid Tumors

Summary: the purpose of the study is to evaluate the safety and tolerability of hlx60 combined with hlx10 in order to determine the maximum tolerated dose (mtd) and recommended phase 2 dose (rp2d) and to evaluate the preliminary efficacy for each combination regimen.

accelerated titration and "3 + 3" dose escalation were used in this trial . various doses of hlx60(anti-garp) combined with hlx10(anti-pd-1) by intravenous infusion.

Eligibility criteria:
inclusion criteria: * patients with histologically or cytologically confirmed advanced malignant solid tumor, who have failed or cannot receive the standard treatment; * with at least one evaluable lesion according to recist v1.1 (for solid tumors); * patients must be able to supply adequate tumor tissue for biomarker (including the expression of pd-l1, garp) analyses; * life expectancy longer than three months; * participant has an eastern cooperative oncology group (ecog) performance status of 0 to 1. exclusion criteria: * has a concurrently active second malignancy, other than adequately treated non-melanoma skin cancers, in situ melanoma or in situ cervical cancer. participants with history of the second malignancy have been disease-free for \<3 years. * has a history of (non-infectious) interstitial lung disease (ild) that required steroids, currently has ild, or when suspected ild cannot be ruled out by imaging at screening. * participant has unresolved aes ≥ grade 2 from prior anticancer therapy except for alopecia. * those who have received anti-garp or anti-garp/tgfβ complex antibody therapy.
gastric venous reconstruction after total pancreatectomy

Conditions: Pancreas Cancer; Pancreatectomy

Summary: total pancreatoduodenectomy (tp) is the standard surgical approach for treatment of extended pancreas tumors. if the gastric coronary vein has to be sacrificed for oncologic or for technical reasons in total pancreatectomy with splenectomy, gastric venous congestion (gvc) may result because all major venous draining routes are terminated. in the sequelae of gvc, gastric venous infarction ultimately leads to gastric perforation with abdominal sepsis. to avoid gastric venous infarction, partial or even total gastrectomy is usually performed in the event of gvc after tp. however, this significantly impacts the patient's quality of life. reconstruction of gastric venous outflow represents a technical approach to overcome gvc and to avoid gastric venous infarction making (partial) gastrectomy unnecessary. the current study aims to assess the role of gastric venous outflow reconstruction in gvc after tp to prevent (partial) gastrectomy.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * provide written informed consent * elective total pancreatectomy for malignant or benign pancreatic lesions or chronic pancreatitis with splenectomy * intraoperative ligation of coronary vein exclusion criteria: * gastric resection due to malignant infiltration * non-reconstructable gastric venous drainage * previous pancreas surgery

Keywords: pancreatectomy gastric venous outflow reconstruction gastric venous congestion
direct statin comparison of ldl-c values: an evaluation of rosuvastatin therapy

Conditions: Hypercholesteremia

Summary: the primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach eas ldl-c target goals after 12 weeks of therapy.


Eligibility criteria:
inclusion criteria: * male or female subjects, age \> 18 years * primary hypercholesterolaemia with cv risk \> 20% (as defined in european guidelines ) and/or type ii diabetes and/or a history of chd or other established atherosclerotic disease. subjects may be lipid-lowering therapy naïve or have been treated for min. 4 weeks with a 'start' dose of any lipid-lowering therapy, which was ineffective. * naïve subjects must have completed 12-weeks dietary counselling before this visit. exclusion criteria: * known heterozygous or homozygous familial hypercholesterolaemia or known type iii hyperlipoproteinaemia (familial dysbetalipoproteinaemia). * documented secondary hypercholesterolaemia of any cause other than named in inclusion criteria 3. * serious or unstable medical condition * statin contraindication

Keywords: high blood cholesterol levels